Alizarin
(1,2-dihydroxyanthraquinone) and purpurin (1,2,4-trihydroxyanthraquinone),
natural anthraquinone compounds from Rubia tinctorum L., are reported to have diverse biological effects including antibacterial,
antitumor, antioxidation, and so on, but the inhibition activity against
amyloid aggregation has been rarely reported. In this study, we used
insulin as a model protein to explore the anti-amyloid effects of
the two compounds. The results showed that alizarin and purpurin inhibited
the formation of insulin fibrils in a dose-dependent manner and reduced
insulin-induced cytotoxicity. Meanwhile, purpurin had a more significant
inhibitory effect on insulin amyloid fibrils compared with alizarin.
In addition, computer simulations indicated that the two compounds
interacted mainly with the hydrophobic residues of insulin chain B
and interfered with the binding of phenylalanine residues. The research
indicated that natural anthraquinone compounds had potential effects
in preventing protein misfolding diseases and could be further used
to design effective antiamyloidosis compounds.